Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital
- PMID: 32864024
- PMCID: PMC7433372
- DOI: 10.14740/gr1275
Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital
Abstract
Background: Cure rates of Clostridium difficile infection (CDI) with fecal microbiota transplant (FMT) have been promising. However, there is debate regarding success of FMT in patients with comorbidities.
Methods: Electronic chart review was done to collect data on patients who underwent FMT from January 2015 to August 2017. Charts were analyzed in November 2018 with a median follow-up of 25.4 months (interquartile range 20 - 31 months).
Results: Twenty patients underwent FMT. The primary success rate at our institution was 90% and overall success rate was 100%. Six patients (43%) had FMT failure (two early and four late).
Conclusions: This case series is a description of our center's initial experience with FMT for treatment of recurrent CDI. Our high success rate reiterates the efficacy and safety of FMT in this population including patients with comorbidities.
Keywords: Clostridium difficile infection; Fecal microbiota transplant; Inflammatory bowel disease.
Copyright 2020, Raghu Subramanian et al.
Conflict of interest statement
Dr Jeffry A Katz: 1) Prometheus Labs advisory board; 2) Boerhinger-Ingelheim advisory board. No disclosures for rest of the authors.
Figures
Similar articles
-
Long-Term Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infection in Patients With and Without Inflammatory Bowel Disease: A Tertiary Care Center's Experience.Gastroenterology Res. 2018 Dec;11(6):397-403. doi: 10.14740/gr1091. Epub 2018 Dec 17. Gastroenterology Res. 2018. PMID: 30627262 Free PMC article.
-
Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease.Inflamm Bowel Dis. 2020 Aug 20;26(9):1415-1420. doi: 10.1093/ibd/izz299. Inflamm Bowel Dis. 2020. PMID: 31821444
-
Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series.Mayo Clin Proc. 2017 Nov;92(11):1617-1624. doi: 10.1016/j.mayocp.2017.08.016. Epub 2017 Nov 1. Mayo Clin Proc. 2017. PMID: 29101931
-
Fecal microbiota transplantation for the treatment of Clostridium difficile infection.J Hosp Med. 2016 Jan;11(1):56-61. doi: 10.1002/jhm.2449. Epub 2015 Sep 7. J Hosp Med. 2016. PMID: 26344412 Free PMC article. Review.
-
Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.Clin Infect Dis. 2019 Apr 8;68(8):1351-1358. doi: 10.1093/cid/ciy721. Clin Infect Dis. 2019. PMID: 30957161
References
-
- Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32(4):387–390. doi: 10.1086/659156. - DOI - PubMed
LinkOut - more resources
Full Text Sources